Anika Therapeutics, Inc.
ANIK
$9.05
$0.688.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 7.84% | -14.49% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.84% | -14.49% | |||
| Cost of Revenue | 20.62% | -10.75% | |||
| Gross Profit | -2.17% | -17.20% | |||
| SG&A Expenses | -5.24% | 13.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.39% | -0.81% | |||
| Operating Income | 2.43% | -4,184.00% | |||
| Income Before Tax | -2.51% | -10,281.58% | |||
| Income Tax Expenses | 665.17% | -96.47% | |||
| Earnings from Continuing Operations | -17.41% | -59.21% | |||
| Earnings from Discontinued Operations | 173.99% | 95.28% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 18.53% | 77.71% | |||
| EBIT | 2.43% | -4,184.00% | |||
| EBITDA | -2.67% | -228.93% | |||
| EPS Basic | 18.90% | 77.28% | |||
| Normalized Basic EPS | -2.07% | -712.68% | |||
| EPS Diluted | 17.62% | 77.07% | |||
| Normalized Diluted EPS | -0.95% | -714.91% | |||
| Average Basic Shares Outstanding | 0.47% | -1.92% | |||
| Average Diluted Shares Outstanding | 1.54% | -2.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||